Skip to content
DataLookout
Menu

NCT03537586

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 9 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words
    • Study completion pushed from Jun 30, 2026 to Jun 30, 2035
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 2 words
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 175 to confirmed 206
    • Site details revised
    v12
  3. Minor Enrollment target: 165 to 175v11
  4. Minor Enrollment target: 135 to 165v9
  5. Minor Enrollment target: 100 to 135
    • Study completion date: Jun 30, 2025 to Jun 30, 2026
    • Interventions: Diagnostic Coronary Angiography with Non-Obstructive CAD (Diagnostic Test) to Adenosine (Drug), Bivalirudin (Drug), Guiding Catheter (Device), Heparin (Drug), Pressure-Temperature Sensor Guidewire (Device)
    v8
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Enrollment target: 25 to 100
    • Primary and study completion dates: Jun 1, 2020 to Jun 30, 2025
    • Site contact updated
    v5
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  3. Minor Start date: Jun 1, 2018 to Jun 29, 2018
    • Site contact updated
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Platelet Activity measured by the Index of Microcirculatory Resistance (IMR)
Timeframe: 12 Months
Measure of Inflammation measured by the Index of Microcirculatory Resistance (IMR)
Timeframe: 12 Months

Arms and interventions

Non-Obstructive CADExperimental

After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells.

Drugs: Bivalirudin, Adenosine, Heparin

Devices: Pressure-Temperature Sensor Guidewire, Guiding Catheter

Sites

1 site in 1 country

  • New York University School of MedicineNew York, New York, United States